Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
复制标题
DOI：
10.1007/s00415-022-11142-7
复制
发表时间：
2022-08
影响因子：
6
通讯作者：
中科院分区：
文献类型：
--
作者：
Assessing the safety of SARS-CoV-2 mRNA vaccines and the effect of immunotherapies on the seroconversion rate in patients with autoimmune neurological conditions (ANC) is relevant to clinical practice. Our aim was to assess the antibody response to and safety of SARS-CoV-2 mRNA vaccines in ANC. This longitudinal study included ANC patients vaccinated with two doses of BNT162b2 or mRNA-1273 between March and August 2021. Side effects were assessed 2–10 days after each dose. Neurological status and anti-spike receptor binding domain antibody levels were evaluated before vaccination and 4 weeks after the second dose. Healthcare-workers served as controls for antibody levels. We included 300 ANC patients (median age 52, IQR 40–65), and 347 healthcare-workers (median age 45, IQR 34–54). mRNA-1273 vaccine was associated with an increased risk of both local (OR 2.52 95% CI 1.45–4.39, p = 0.001) and systemic reactions (OR 2.51% CI 1.49–4.23, p = 0.001). The incidence of relapse was not different before and after vaccine (Incidence rate ratio 0.72, 95% CI 0.29–1.83). Anti-SARS-CoV-2 IgG were detected in 268 (89.9%) patients and in all controls (p < 0.0001). BNT162b2 vaccine (OR 8.84 95% CI 2.32–33.65, p = 0.001), anti-CD20 mAb (OR 0.004 95% CI 0.0007–0.026, p < 0.0001) and fingolimod (OR 0.036 95% CI 0.002–0.628, p = 0·023) were associated with an increased risk of not developing anti-SARS-CoV-2 IgG. SARS-CoV-2 mRNA vaccines were safe in a large group of ANC patients. Anti-CD20 and fingolimod treatment, as well as vaccination with the BNT162b2 vaccine, led to a reduced humoral response. These findings could inform vaccine policies in ANC patients undergoing immunotherapy. The online version contains supplementary material available at 10.1007/s00415-022-11142-7.
登录
查看更多内容
影响因子：
4
作者：
Novak F;Nilsson AC;Nielsen C;Holm DK;Østergaard K;Bystrup A;Byg KE;Johansen IS;Mittl K;Rowles W;Mcpolin K;Spencer C;Sagan S;Gerungan C;Wilson MR;Zamvil SS;Bove R;Sabatino JJ;Sejbaek T
通讯作者：
Sejbaek T
影响因子：
11.1
作者：
Sormani MP;Inglese M;Schiavetti I;Carmisciano L;Laroni A;Lapucci C;Da Rin G;Serrati C;Gandoglia I;Tassinari T;Perego G;Brichetto G;Gazzola P;Mannironi A;Stromillo ML;Cordioli C;Landi D;Clerico M;Signoriello E;Frau J;Ferrò MT;Di Sapio A;Pasquali L;Ulivelli M;Marinelli F;Callari G;Iodice R;Liberatore G;Caleri F;Repice AM;Cordera S;Battaglia MA;Salvetti M;Franciotta D;Uccelli A;CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS
通讯作者：
CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS
DOI：
10.1016/s2665-9913(21)00222-8
发表时间：
2021-11
期刊：
The Lancet. Rheumatology
影响因子：
--
作者：
Boekel L;Steenhuis M;Hooijberg F;Besten YR;van Kempen ZLE;Kummer LY;van Dam KPJ;Stalman EW;Vogelzang EH;Cristianawati O;Keijzer S;Vidarsson G;Voskuyl AE;Wieske L;Eftimov F;van Vollenhoven R;Kuijpers TW;van Ham SM;Tas SW;Killestein J;Boers M;Nurmohamed MT;Rispens T;Wolbink G
通讯作者：
Wolbink G
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.9
作者：
Achiron A;Mandel M;Dreyer-Alster S;Harari G;Magalashvili D;Sonis P;Dolev M;Menascu S;Flechter S;Falb R;Gurevich M
通讯作者：
Gurevich M